Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
15.97
-0.11 (-0.72%)
Jan 22, 2026, 2:57 PM EST - Market open
Takeda Pharmaceutical Employees
Takeda Pharmaceutical Company had 47,455 employees as of March 31, 2025. The number of employees decreased by 1,826 or -3.71% compared to the previous year.
Employees
47,455
Change (1Y)
-1,826
Growth (1Y)
-3.71%
Revenue / Employee
$628,950
Profits / Employee
$4,710
Market Cap
50.15B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 47,455 | -1,826 | -3.71% |
| Mar 31, 2024 | 49,281 | 186 | 0.38% |
| Mar 31, 2023 | 49,095 | 1,748 | 3.69% |
| Mar 31, 2022 | 47,347 | 248 | 0.53% |
| Mar 31, 2021 | 47,099 | -396 | -0.83% |
| Mar 31, 2020 | 47,495 | -2,083 | -4.20% |
| Mar 31, 2019 | 49,578 | 22,348 | 82.07% |
| Mar 31, 2018 | 27,230 | -2,670 | -8.93% |
| Mar 31, 2017 | 29,900 | -1,268 | -4.07% |
| Mar 31, 2016 | 31,168 | -160 | -0.51% |
| Mar 31, 2015 | 31,328 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Teva Pharmaceutical Industries | 36,830 |
| Viatris | 32,000 |
| Dr. Reddy's Laboratories | 27,811 |
| Haleon | 24,561 |
| Zoetis | 13,800 |
| Elanco Animal Health | 9,450 |
| Neurocrine Biosciences | 1,800 |
| Alkermes | 1,800 |
TAK News
- 7 hours ago - Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1 - Business Wire
- 9 days ago - Takeda Pharmaceutical Company Limited (TAK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 17 days ago - Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) - Business Wire
- 5 weeks ago - Takeda's AI-crafted psoriasis pill succeeds in late-stage studies - Reuters
- 5 weeks ago - Takeda's Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment - Business Wire
- 6 weeks ago - Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera - Business Wire
- 6 weeks ago - Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies - PRNewsWire
- 2 months ago - US FDA investigates death tied to Takeda's blood disorder drug - Reuters